Acute MigrainePhase 3NCT07674654
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
A Phase 3 study testing Elismetrep in people with Acute Migraine, run by TriGemX Bio, Inc. at 113 sites in United States.
Trial summary
This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Migraine
- What is being tested?
- Elismetrep
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,000 participants
- Where
- 113 sitesUnited States
- Study dates
- 3 Aug 2026to Jun 2028
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participant completing an acute treatment trial of elismetrep (Study K-304 P003; attending the EoS Visit 3 within the allowed visit window of the acute treatment study), treated a qualifying migraine in that study, was at least 80% compliant with the daily e-Diary 'check-ins' in the base study and completed the 2-hour and 4-hour post-dose assessments in the eDiary.
- Note: If a subject treats their qualifying migraine in the base study within 5 days of randomization (i.e. ≤ 4 daily check-ins should have been completed in the eDiary), they are eligible for this study if they missed 1 daily check-in, even though compliance was <80%;
- Participant voluntarily agrees to participate in the study by giving written informed consent;
- Participant is able to read, understand, and complete the study questionnaires and diary;
- Participant is willing and able to comply with the study schedule of visits, all trial procedures and restrictions;
- Participant is willing to use his/her own personal, qualified smartphone to download any specific eDiary applications for use for the entire duration of the study;
Show all 10Show fewer
- For females of reproductive potential (as determined in the base study), continues to agree to remain abstinent from heterosexual activity or a. Agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the EoS visit.
- Acceptable methods of birth control are:
- Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal. ii. Progestogen-only hormonal contraception associated with inhibition of ovulation: oral; injectable; implantable; intrauterine device; intrauterine hormone-releasing system; bilateral tubal occlusion; vasectomized partner; sexual abstinence*; progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action; male or female condom with or without spermicide; cap, diaphragm or sponge with spermicide; a combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods).
- Abstinence can be used as the sole method of contraception if it is in line with the participant's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.
Who cannot join
- Is a female who is pregnant, breast-feeding, or intends to become pregnant during the planned course of the study. Note: Participants must have a negative urine pregnancy result at the base study EoS/Visit 3 (i.e., pre-randomization for this study);
- Has, at the time of the base study EoS/Visit 3, had any change in medical history or a laboratory finding since screening in the acute treatment study that in the opinion of the investigator renders the participant unsuitable for this study (e.g., development of a finding that would have precluded participation in the base acute treatment study);
- Participant is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS) taken during the base study E0S/Visit 3, or of harm to others in the opinion of the investigator. Participants must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in 'since last version' version of the C-SSRS;
- Participant is currently in violation of study requirements for prohibited and permissible concomitant medications or treatments (not already specified in other criteria) or is anticipated to violate these requirements during trial participation) as assessed for the base study E0S/Visit 3;
- Has any major surgery scheduled for the duration of the trial;
- Has any other unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with the interpretation of efficacy and/or safety results;
Show all 9Show fewer
- At Visit 1, has an open/ongoing adverse event from the base study EoS visit;
- Experienced a serious adverse event in the base study;
- Has previous participation in this trial. Participation is defined as signed informed consent following completion of the base study EoS/Visit 3 procedures.
Trial locations and contacts
113 sites in 1 country. Contact the study team or a site near you to ask about taking part.
113 sites in 1 country
United States113 sites, 113 recruiting
- Recruiting
Albuquerque Clinical Trials
Albuquerque, New Mexico, 87102
- Recruiting
Lehigh Center for Clinical Research
Allentown, Pennsylvania, 18103
- Recruiting
Dent Neuro Institute, Buffalo
Amherst, New York, 14226
- Recruiting
Michigan Headache Pain & Neurological Institute
Ann Arbor, Michigan, 48104
- Recruiting
DelRicht Research
Atlanta, Georgia, 30329
- Recruiting
FutureSearch Trials of Neurology
Austin, Texas, 78731
- Recruiting
Tekton Research
Austin, Texas, 78745
- Recruiting
Physicians to Children & Adolescents, PSC (Kentucky Pediatric / Adult Research)
Bardstown, Kentucky, 40004
- Recruiting
Central Research Associates, LLC (CRA) dba Flourish Research
Birmingham, Alabama, 35205
- Recruiting
Boston Clinical Trials - Alcanza
Boston, Massachusetts, 02131
- Recruiting
Pantheon Clinical Research
Bountiful, Utah, 84010
- Recruiting
SPRI Clinical Trials, LLC
Brooklyn, New York, 11235
- Recruiting
IMMUNOe Research Centers
Centennial, Colorado, 80112
- Recruiting
Crescent City Headache & Neurology Center
Chalmette, Louisiana, 70043
- Recruiting
TrialSphere
Chandler, Arizona, 85286
- Recruiting
OnSite Clinical Solutions
Charlotte, North Carolina, 28277
- Recruiting
WR-ClinSearch, LLC
Chattanooga, Tennessee, 37421
- Recruiting
Cedar Crosse Research Center
Chicago, Illinois, 60607
- Recruiting
Chicago Headache Center & Research Institute
Chicago, Illinois, 60657
- Recruiting
StudyMetrix Research
City of Saint Peters, Missouri, 63303
- Recruiting
MCB Clinical Research Centers
Colorado Springs, Colorado, 80910
- Recruiting
Axiom Research, LLC
Colton, California, 92324
- Recruiting
Hometown Research
Columbus, Ohio, 43228
- Recruiting
True North Neurology
Commack, New York, 11725
- Recruiting
ProScience Research Group
Culver City, California, 90230
- Recruiting
APD Clinical Research
Cypress, Texas, 77372
- Recruiting
Horizon Clinical Research and Gill Neuroscience
Cypress, Texas, 77429
- Recruiting
FutureSearch Trials of Dallas, LP
Dallas, Texas, 75251
- Recruiting
J. Lewis Research, Inc. / Foothill Family Clinic Draper
Draper, Utah, 84020
- Recruiting
OK Clinical Research, LLC
Edmond, Oklahoma, 73034
- Recruiting
Leading Edge Research LA, LLC
Encino, California, 91316
- Recruiting
Healthcare Research Network II, LLC
Flossmoor, Illinois, 60447
- Recruiting
Advanced Neurosciences Research
Fort Collins, Colorado, 80528
- Recruiting
Guilford Neurologic Research Partners, LLC
Greensboro, North Carolina, 27405
- Recruiting
Headache Wellness Center
Greensboro, North Carolina, 27405
- Recruiting
DelRicht Research
Gulfport, Mississippi, 39503
- Recruiting
Healthcare Research Network
Hazelwood, Missouri, 63042
- Recruiting
Victorium Clinical Research
Houston, Texas, 77024
- Recruiting
DM Clinical Research
Houston, Texas, 77081
- Recruiting
Axiom Research, Orange County
Irvine, California, 92604
- Recruiting
AMR Clinical - Kansas City
Kansas City, Missouri, 64114
- Recruiting
Clinical Investigation Specialists, Inc.
Kenosha, Wisconsin, 53144
- Recruiting
GMG Clinical Research, LLC dba Radiance Clinical Research
Lampasas, Texas, 76550
- Recruiting
IMA Clinical Research - Las Vegas
Las Vegas, Nevada, 89102
- Recruiting
Excel Clinical Research
Las Vegas, Nevada, 89109
- Recruiting
Wake Research Las Vegas Rainbow
Las Vegas, Nevada, 89118
- Recruiting
AMR Clinical - Las Vegas
Las Vegas, Nevada, 89119
- Recruiting
Redbird Research
Las Vegas, Nevada, 89119
- Recruiting
AMR Clinical - Lexington
Lexington, Kentucky, 40509
- Recruiting
CTI Clinical Research Center
Lexington, Kentucky, 45212
- Recruiting
Arkansas Clinical Research
Little Rock, Arkansas, 72205
- Recruiting
Downtown L.A. Research Center, Inc.
Los Angeles, California, 90017
- Recruiting
Clinical Research Institute
Los Angeles, California, 90048
- Recruiting
Central New York Clinical Research
Manlius, New York, 13104
- Recruiting
Drug Studies America
Marietta, Georgia, 30060
- Recruiting
Hometown Research
Milford, Ohio, 45150
- Recruiting
Clinical Research Institute
Minneapolis, Minnesota, 55402
- Recruiting
M3 Wake Research - Mission Mental Health (WR-MMH)
Mission Viejo, California, 92691
- Recruiting
AMR Mobile
Mobile, Alabama, 36608
- Recruiting
Frontier Clinical Research
Morgantown, West Virginia, 26505
- Recruiting
Chicago Headache Center & Research Institute
Naperville, Illinois, 60563
- Recruiting
Access Clinical Trials Inc
Nashville, Tennessee, 37203
- Recruiting
Clinical Research Associates, Inc.
Nashville, Tennessee, 37203
- Recruiting
DelRicht Research
New Orleans, Louisiana, 70115
- Recruiting
Fieve Clinical Research, Inc
New York, New York, 10017
- Recruiting
Health Research of Hampton Roads, Inc. (HRHR)
Newport News, Virginia, 23606
- Recruiting
AMR Clinical - Norfolk
Norfolk, Virginia, 23502
- Recruiting
Coastal Carolina Research Center
North Charleston, South Carolina, 29405
- Recruiting
Las Vegas Clinical Trials
North Las Vegas, Nevada, 89030
- Recruiting
Excell Research
Oceanside, California, 92056
- Recruiting
Advanced Research Institute
Ogden, Utah, 84405
- Recruiting
Hightower Clinical
Oklahoma City, Oklahoma, 73102
- Recruiting
Collective Medical Research
Overland Park, Kansas, 66212
- Recruiting
Clinical Associates Midwest, LLC
Overland Park, Kansas, 66214
- Recruiting
Clinical Research Philadelphia
Philadelphia, Pennsylvania, 19114
- Recruiting
Headlands Research - PharmaSite
Pikesville, Maryland, 21208
- Recruiting
Preferred Primary Care Physicians, Inc.
Pittsburgh, Pennsylvania, 15236
- Recruiting
Aim Trials, LLC
Plano, Texas, 75093
- Recruiting
Empire Clinical Research
Pomona, California, 91767
- Recruiting
The Neurology Group
Pomona, California, 91767
- Recruiting
Summit Research Network
Portland, Oregon, 97210
- Recruiting
Advanced Research Institute-Portland
Portland, Oregon, 97223
- Recruiting
Eximia Research - NC, LLC
Raleigh, North Carolina, 27607
- Recruiting
Advanced Research Institute-Reno
Reno, Nevada, 89511
- Recruiting
Proven Endpoints
Ridgeland, Mississippi, 39157
- Recruiting
Artemis Institute for Clinical Research
Riverside, California, 92503
- Recruiting
Granger Medical Clinic
Riverton, Utah, 84096
- Recruiting
Rochester Clinical Research
Rochester, New York, 14609
- Recruiting
J. Lewis Research, Inc. / Foothill Family Clinic
Salt Lake City, Utah, 84109
- Recruiting
J. Lewis Research, Inc. / Foothill Family Clinic
Salt Lake City, Utah, 84121
- Recruiting
Acclaim Clinical Research
San Diego, California, 92120
- Recruiting
Frontier Clinical Research, LLC
Scottdale, Pennsylvania, 15683
- Recruiting
Seattle Clinical Research Center
Seattle, Washington, 98104
- Recruiting
Carolina Research Center, Inc
Shelby, North Carolina, 28150
- Recruiting
CenExel Sherman Oaks CA (California Neuroscience Research)
Sherman Oaks, California, 91403
- Recruiting
Frontier Clinical Research, LLC
Smithfield, Pennsylvania, 15478
- Recruiting
Encompass Clinical Research
Spring Valley, California, 91978
- Recruiting
Clinvest Headlands LLC
Springfield, Missouri, 65807
- Recruiting
Sundance Clinical Research
St Louis, Missouri, 63141
- Recruiting
Sleep Care Research Institute d/b/a Clinical Research Atlanta-Stockbridge
Stockbridge, Georgia, 30281
- Recruiting
DelRicht Research
Tulsa, Oklahoma, 74133
- Recruiting
Sunwise Clinical Research
Walnut Creek, California, 94596
- Recruiting
Diablo Clinical Research
Walnut Creek, California, 94598
- Recruiting
MedVadis Research Corporation, LLC
Waltham, Massachusetts, 02451
- Recruiting
Chase Medical Research, LLC
Waterbury, Connecticut, 06708
- Recruiting
ClinPoint Trials
Waxahachie, Texas, 75165
- Recruiting
CincyScience
West Chester, Ohio, 45069
- Recruiting
Kinetic Clinical Research
West Covina, California, 91790
- Recruiting
Integrated Clinical Trials Solution
West Des Moines, Iowa, 50265
- Recruiting
Focus Clinical Research
West Hills, California, 91307
- Recruiting
Heartland Research Associates, LLC - An AMR Company
Wichita, Kansas, 67207
- Recruiting
Upstate Clinical Research Associates
Williamsville, New York, 14221
- Recruiting
Tekton Research, Inc.
Yukon, Oklahoma, 73099
About this study
This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.
- Conditions
- Acute Migraine
- Being tested
- Elismetrep
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ElismetrepDrug
Also called K-304
Administered orally
| Study group | Role | What they receive |
|---|---|---|
| Elismetrep 10 mg | Experimental | Participants were randomised to receive elismetrep at a dose of 10 mg Receives: Drug: Elismetrep |
| Elismetrep 20 mg | Experimental | Participants were randomised to receive elismetrep at a dose of 20 mg Receives: Drug: Elismetrep |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of participants with at least one treatment-emergent adverse event (TEAE)
Measured: Through study completion, an average of 1 year
Proportion of participants with at least one treatment-emergent serious adverse event (SAE)
Measured: Through study completion, an average of 1 year
Proportion of participants with TEAEs leading to study drug discontinuation
Measured: Through study completion, an average of 1 year
Proportion of participants with TEAEs that occur in at least 5% of treated participants in either treatment arm
Measured: Through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2026
- Study start3 Aug 2026
- Primary completionJun 2028 (estimated)
- Study completionJun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute MigraineStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- TriGemX Bio, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07674654
- Sponsor's protocol ID
- K-304 P005
- Status last verified
- Aug 2026
- First submitted
- 15 Jun 2026
- Last updated
- 2 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- ClinicalTrials.gov ID
- NCT07674654
- Acronym / sponsor ID
- K-304 P005
- Conditions
- Acute Migraine
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- TriGemX Bio, Inc.Industry (pharma, biotech, devices)
- Study start
- 3 Aug 2026 (actual)
- Primary completion
- Jun 2028 (estimated)
- Study completion
- Jun 2028 (estimated)
- First posted
- 29 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Elismetrep 10 mg | Experimental | Drug: ElismetrepParticipants were randomised to receive elismetrep at a dose of 10 mg |
| Elismetrep 20 mg | Experimental | Drug: ElismetrepParticipants were randomised to receive elismetrep at a dose of 20 mg |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Participant completing an acute treatment trial of elismetrep (Study K-304 P003; attending the EoS Visit 3 within the allowed visit window of the acute treatment study), treated a qualifying migraine in that study, was at least 80% compliant with the daily e-Diary 'check-ins' in the base study and completed the 2-hour and 4-hour post-dose assessments in the eDiary.
- Note: If a subject treats their qualifying migraine in the base study within 5 days of randomization (i.e. ≤ 4 daily check-ins should have been completed in the eDiary), they are eligible for this study if they missed 1 daily check-in, even though compliance was <80%;
- Participant voluntarily agrees to participate in the study by giving written informed consent;
- Participant is able to read, understand, and complete the study questionnaires and diary;
- Participant is willing and able to comply with the study schedule of visits, all trial procedures and restrictions;
Key exclusion criteria (9 listed)
- Is a female who is pregnant, breast-feeding, or intends to become pregnant during the planned course of the study. Note: Participants must have a negative urine pregnancy result at the base study EoS/Visit 3 (i.e., pre-randomization for this study);
- Has, at the time of the base study EoS/Visit 3, had any change in medical history or a laboratory finding since screening in the acute treatment study that in the opinion of the investigator renders the participant unsuitable for this study (e.g., development of a finding that would have precluded participation in the base acute treatment study);
- Participant is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS) taken during the base study E0S/Visit 3, or of harm to others in the opinion of the investigator. Participants must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in 'since last version' version of the C-SSRS;
- Participant is currently in violation of study requirements for prohibited and permissible concomitant medications or treatments (not already specified in other criteria) or is anticipated to violate these requirements during trial participation) as assessed for the base study E0S/Visit 3;
- Has any major surgery scheduled for the duration of the trial;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ElismetrepAlso: K-304Administered orally | Drug | Elismetrep 10 mg, Elismetrep 20 mg |
Primary outcome
Proportion of participants with at least one treatment-emergent adverse event (TEAE)
Time frame: Through study completion, an average of 1 year
Proportion of participants with at least one treatment-emergent serious adverse event (SAE)
Time frame: Through study completion, an average of 1 year
Proportion of participants with TEAEs leading to study drug discontinuation
Time frame: Through study completion, an average of 1 year
Proportion of participants with TEAEs that occur in at least 5% of treated participants in either treatment arm
Time frame: Through study completion, an average of 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Acute Migraine
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Migraine
RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Migraine
Active, not recruitingObservational study
Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to Defined Target Populations
Migraine
Active, not recruitingObservational study
Consistency of Response With Rimegepant in Acute Treatment of Migraine
Migraine
RecruitingPhase 3
Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)
Post Traumatic Headache
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
113 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Elismetrep in people with Acute Migraine, run by TriGemX Bio, Inc. at 113 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 113 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Annemarie Vance (917-336-3654, annemarie@kallyope.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of participants with at least one treatment-emergent adverse event (TEAE) (time frame: Through study completion, an average of 1 year). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2026.